Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

OBJECTIVE: To compare efficacy and safety of dulaglutide at doses of 3.0 and 4.5 mg versus 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin. RESEARCH DESIGN AND METHODS: Patients were randomly assigned to once-weekly dulaglutide 1.5 mg, 3.0 mg, or 4.5 mg for 52 weeks. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Frias, Juan P., Bonora, Enzo, Nevarez Ruiz, Luis, Li, Ying G., Yu, Zhuoxin, Milicevic, Zvonko, Malik, Raleigh, Bethel, M. Angelyn, Cox, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896253/
https://www.ncbi.nlm.nih.gov/pubmed/33397768
http://dx.doi.org/10.2337/dc20-1473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896253/
https://www.ncbi.nlm.nih.gov/pubmed/33397768
http://dx.doi.org/10.2337/dc20-1473

Ejemplares similares